Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

The California biotech has drawn partnerships with Eli Lilly and J&J on the promise of its approach to rebalancing the immune ...

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitis ZORYVE, a next-generation topical phosphodiesterase-4 ...

Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the treatment of atopic dermatitis in adults and ...

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

The biotech expects three Phase 2 readouts in urticaria and eczema over the next two years, and will keep its “options open” ...

Over the last 3 months, EPS estimates have seen 0 upward revisions and 13 downward. Revenue estimates have seen 16 upward ...

BTIG raised the firm’s price target on Apogee Therapeutics (APGE) to $100 from $81 and keeps a Buy rating on the shares. Eli Lilly (LLY) ...

Credit: Pormezz/Shutterstock. Eli Lilly’s EBGLYSS has demonstrated improvement in skin condition and itch relief in patients with moderate-to-severe atopic dermatitis, according to new results from ...